Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Next Previous
Trial Profile

A Randomized, Double-Blind, Placebo-Controlled Phase II Study to Determine the Safety and Efficacy of Oral Ifetroban in Patients With Idiopathic Pulmonary Fibrosis (IPF)

Status: Recruiting
Phase of Trial: Phase II

Latest Information Update: 21 May 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Ifetroban (Primary)
  • Indications Idiopathic pulmonary fibrosis; Interstitial lung diseases; Pulmonary fibrosis
  • Focus Therapeutic Use
  • Acronyms FIGHTING FIBROSIS
  • Sponsors Cumberland Pharmaceuticals

Most Recent Events

  • 13 May 2025 According to a Cumberland Pharmaceuticals media release, Cumberland Pharmaceuticals and Qureight formed a partnership to enhance the output of data from this study.Under this partnership, Qureight's AI-driven analytics technologies will be used to quantify changes in multiple imaging biomarkers, using computed tomography (CT) data from patients in this study .
  • 05 Mar 2024 According to a Cumberland Pharmaceuticals media release, this study will be conducted over 20 medical centers of excellence across the United States.
  • 01 Feb 2024 Planned End Date changed from 1 Dec 2026 to 1 Jan 2026.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top